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Abstract Newborn metabolic screening is the most wide-
spread application of screening technology and provides the
most comprehensive application of genetics in health serv-
ices, where the Guthrie blood spot cards allow screening for
metabolic diseases in close to 100 % of all newborn babies.
Despite over 40 years of use and significant benefits to well
in excess of 100,000 children worldwide, there is remark-
ably little consensus in what conditions should be screened
for and response to new advances in medicine relating to
programme expansion. In this article, the international cri-
teria for newborn metabolic screening are considered, and
we propose that these criteria are poorly developed in rela-
tion to the baby, its family and society as a whole.
Additionally, the ethical issues that should inform the appli-
cation of screening criteria are often not developed to a level
where a consensus might easily be achieved. We also con-
sider that when family interests are factored in to the
decision-making process, they have a significant influence
in determining the list of diseases in the panel, with
countries or states incorporating family and societal values
being the most responsive. Based on our analysis, we pro-
pose that decision criteria for metabolic screening in the
newborn period should be adapted to specifically include
parent and family interests, community values, patients’
rights, duties of government and healthcare providers, and
ethical arguments for action in the face of uncertainty.
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Introduction—the context of pregnancy, childbirth
and neonatal screening
Newborn metabolic screening is a distinct subset of the varied
screenings that are available in the prenatal and neonatal
period. Maternity care revolves around many screens for
maternal infections, blood pressure, gestational diabetes, fetal
abnormalities and other risks to the mother and fetus. The
identification of such risks permits a range of interventions to
prevent serious health problems for mother and baby through-
out the pregnancy and birth process. Furthermore, after birth
there are screening options for hearing loss (White et al. 1994;
Yoshinaga-Itano 2004), metabolic diseases (Garg and
Dasouki 2006; Yoon et al. 2005) and other physical disorders
(Fisher 1991; Pass et al. 2000; Quinn et al. 1977).
Public health screening programmes are rare occurrences
in maternity care, with non-programme screening being a
more common practice. Referred to as ‘opportunistic screen-
ing’ or ‘standard medical practice’, the health professional
evaluates and tailors the tests to the patient’s individual
circumstances. In contrast, other screening tests are offered
to all people falling into a particular category, as part of a
planned public health programme, which are largely based
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on the ten principles proposed by Wilson and Jungner
(1968) primarily formulated in relation to cancer detection;
however, since that report additional criteria have been
considered in the context of medical and screening practice
in the twenty-first century (Andermann et al. 2008). These
programmes have significant implications, both for individ-
uals offered tests and for health systems in general. As
discussed below, there are detailed analyses against criteria
for screening programmes, including cost benefits and as-
sessment of potential benefits and harms, and programme
standards and quality measures, before such programmes
are established. More recently, there have been moves to
introduce new forms of screening which are specifically
pregnancy and child birth-related into formal public health
programmes. This includes antenatal HIV, antenatal fetal
aneuploidy and newborn hearing tests. However, the most
universally accepted and long-standing programme in most
developed countries is newborn metabolic screening.
Overall, these are well-run programmes with little harm to
the newborn; however, it is our belief that the use of the
screening programmes could be more effective if broader
considerations are given to the overall welfare of the family
and the overall principles proposed by Andermann et al.
(2008) as well as the identification of a specific disease in
the newborn. Here, we will consider the background of
newborn metabolic screening in the context of benefit in
relation to respect for autonomy, ethical conduct and choice
within the family.
Newborn metabolic screening programme: a short
history
Newborn metabolic screening evolved from Guthrie and
Susi (1963) test for metabolites from dried blood spots.
Using a bacterial inhibition assay whereby the growth of
Bacillus subtilis is enhanced in the presence of phenylala-
nine, he was able to identify babies with phenylketonuria
(PKU) prior to clinical presentation. As is common in most
metabolic disorders, once PKU symptoms are apparent,
cellular damage has already occurred. Newborn blood test
screening permits early recognition and enables dietary in-
tervention to prevent the severe mental retardation that
would inevitably occur as a consequence of the enzyme
phenylalanine hydrolase deficiency or mutations in the en-
zyme (Hansen 1975; Walter 1998). The ‘PKU test’, as it is
known, has been embraced by all modern health systems
and is widely regarded as an exemplar of a successful public
health screening programme.
Later, an increase in knowledge and technology allowed
for the testing of an increasing number of diseases from the
same blood spots (Clague and Thomas 2002). For instance,
starting in the 1970s (1981 in New Zealand), congenital
hypothyroidism (CH) has been widely adopted by screening
programmes (Ehrlich and McKendry 1973; Fisher 1991;
National Testing Centre 2010; Taranger et al. 1973). The
test detects thyroid-stimulating hormone deficiency, allow-
ing early treatment to prevent the onset of severe physical
and mental deterioration.
Generally, beyond this consensus on the use of PKU and
CH screening programmes, the adoption of other tests is
geographically variable (Clague and Thomas 2002). For
example, in New Zealand, galactosemia, congenital adrenal
hyperplasia, biotinidase deficiency, cystic fibrosis (CF) and
maple syrup urine disease were successively added to the
list of screening conditions, over the 1970s and 1980s
(National Testing Centre 2010). In other countries, opportu-
nities were taken to add additional tests to the screening
programme such as haemoglobinopathies as a result of high
carrier rates in specific populations (Benson and Therrell
2010; Streetly and Dick 2005). However, prior to expanded
screening on an international basis, the number of tests in
each health system or US state ranged from as few as two or
three up to seven (Watson et al. 2006). During the1990s,
advances in technology led to the development of tandem
mass spectrometry, with the capacity to accurately screen for
a much larger number of rare metabolic diseases (Hill 1993;
Jones and Bennett 2002; Röschinger et al. 2003). By 2007,
screening was underway for an average of about 27 meta-
bolic disorders throughout most US states, parts of Canada
and all of Australia and New Zealand (Sharrard and Pollitt
2007). In contrast, despite a modest increase in screening
targets in Britain and other parts of Canada, there are still
considerably fewer tests offered by so-called expanded
screening programmes. There is substantial literature that
is either supportive (Tarini 2007; Avard et al. 2007; Lin and
Fleischman 2008; Alexander and van Dyck 2006; Howell
2006) or critical/cautious about expanded newborn screen-
ing (Bailey and Murray 2008; Moyer et al. 2008; Grosse et
al. 2006; Botkin et al. 2006). Internationally, some jurisdic-
tions are noted for their prompt uptake of the associated
technologies, with others slow and seemingly reluctant to
follow the trend (Green et al. 2006; Padilla et al. 2010).
Adding to the contention about further expansion of
screening is debate about how to respond to technological
advancement that makes it technically possible to screen for
Fragile X (Bailey and Murray 2008; Coffee et al. 2009),
lysosomal storage diseases (Li et al. 2004; Meikle et al.
2006), immune deficiencies (Cassol et al. 1994; Puck
2007), Duchenne muscular dystrophy (Parsons and
Bradley 2008; van Ommen and Scheuerbrandt 1993) and
other rare disorders (Röschinger et al. 2003).
Differentials in the uptake of disorders into screening
programmes are suggestive of discrepancies between
screening criteria and a lack of international standardization
(Tuuminen et al. 1994). The development of screening
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programmes and the differences that have evolved are the
consequence of context-specific interpretations of and
amendments to screening criteria (Clague and Thomas
2002; Padilla et al. 2010). Moreover, they are also dictated
by financial resources, incidence rate, the strength of patient
advocacy and cultural differences (Pollitt 2007).
Screening criteria
Screening criteria originated from a well-cited paper by
Wilson and Jungner (1968) that was commissioned by the
World Health Organisation (WHO). Wilson and Jungner’s
criteria were primarily formulated in the context of screen-
ing for adult diseases specifically carcinomas and hepatitis
B (Table 1). The authors’ intention was for the criteria to be
adapted and developed within differing situations, as op-
posed to strict adherence to a formula. However, in practice,
many health systems appear to regard them as static, rather
than an evolving regime. They are frequently referred to as a
‘gold standard’ for screening (Andermann et al. 2008).
Although Wilson and Jungner’s criteria have undergone
some refinement to incorporate issues such as the validity
of tests (Cochrane and Holland 1971), they nevertheless
remain as a set of criteria that have attained a state of almost
biblical reverence for many commentators.
However, this poses difficulties when attempts are made
to impose the criteria in the context of dissimilar disease
categories, such as newborn metabolic screening. Indeed,
Wilson and Jungner noted that it was at an early develop-
mental phase at the time, and consequently did not factor
newborn metabolic screening into the development of their
criteria (Wilson and Jungner 1968). In contrast to cancer
screening, situations such as newborn screening for a range
of diseases are distinct in their nature. For instance, the
newborn baby lacks the autonomy of an adult who decides
to undergo screening for cancer. Instead, these decisions are
made by and directly impact upon the baby’s parents, an
additional complication that needs special consideration.
Despite this, there has been no international consensus on an
appropriate set of criteria for the newborn context (Clague and
Thomas 2002; Padilla et al. 2010; Tuuminen et al. 1994). In
order to explore how these difficulties are managed in prac-
tice, we now turn to a specific case study: New Zealand.
Screening criteria in New Zealand: the case of cystic
fibrosis
New Zealand was an early adopter of newborn metabolic
screening and set up one of the first national screening
programmes for all newborns in 1969 (National Testing
Centre 2010). In 2003, the National Health Committee
(NHC) updated their assessment criteria for health screening
programmes in New Zealand. The NHC document outlines
five components that constitute what they term a ‘quality’
programme: safety, consumer focus, access, effectiveness
and efficiency. Screening assessments criteria are also iden-
tified that are consistent with the WHO formula, albeit with
the addition of social, ethical and cost–benefit considera-
tions (National Health Committee 2003).
Although these criteria appear to be robust, there is little
reference to the context of newborn screening; in particular,
how the formula should be applied in practice. With a
primary analysis of the screening scenarios of four types
of cancer and hepatitis B, the report makes only two refer-
ences to newborn screening. The first reference is in a list of
examples of screening in New Zealand; the second is a brief
comment on the ethical issues surrounding the consent
process in relation to screening children. With an absence
of guidance on how to implement the screening criteria in
the practice of newborn screening, some interpretation and
flexibility in applying them is both needed and used. To
demonstrate this, we explore how this has occurred at
ground level in the context of screening for CF.
CF is a disease that leads to increasing disability and in
many cases, early mortality (Ramsey 1996). Whilst it affects
the entire body, the most common symptom is breathing
Table 1 The principles proposed by Wilson and Jungner (1968) for the early detection of disease
1. The condition sought should be an important health problem.
2. There should be an accepted treatment for patients with recognized disease.
3. Facilities for diagnosis and treatment should be available.
4. There should be a recognizable latent or early symptomatic stage.
5. There should be a suitable test or examination.
6. The test should be acceptable to the population.
7. The natural history of the condition, including development from latent to declared disease, should be adequately understood.
8. There should be an agreed policy on whom to treat as patients.
9. The cost of case finding (including diagnosis and treatment of patients diagnosed) should be economically balanced in relation to possible
expenditure on medical care as a whole.
10. Case finding should be a continuing process and not a “once and for all” project.
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difficulties that result from frequent lung infections and
increased secretions. Other symptoms include poor growth,
sinus infections, diarrhoea, scarring of the pancreas and
infertility. It is an autosomal recessive mutation in the cystic
fibrosis transmembrane conductive regulator gene resulting
in abnormal regulation of the components of mucus, sweat
and digestive enzymes (Bush and Gotz 2006).
Following work by Crossley et al. (1979) at the University
of Auckland, cystic fibrosis was introduced as a research
project into the New Zealand newborn metabolic screening
programme in 1983. However, the Ministry of Health was
reluctant to provide for its continuation. Whether the
Ministry’s reasons were based on compliance with screening
criteria, on cost, on cost effectiveness based on outcomes for
the child, or all of these combined is not clear, but following
significant support group lobbying, a decision to retain the
project on a permanent basis was made at a political level.
Whilst cystic fibrosis did not strictly adhere to the WHO
screening criteria, the crux of the argument for continued
inclusion in the newborn screening programme revolved
around early identification and early intervention, including
family knowledge of inheritance risk. Consequently, whilst
there was, and still is, no fully effective treatment for cystic
fibrosis, newborn screening has enabled early intervention
in 354 New Zealand cases (National Testing Centre 2010)
that occurred from 1983 to December 2010. There is uncer-
tainty about the individual contributions of each factor, but it
is clear that the combined effect of early detection and
intervention, and treatment advances, permits patients who
would invariably die as children to live well into adulthood.
Cystic fibrosis, largely as a result of screening, but also
helped by improved medicines, has been transformed from
a disease that was usually fatal in childhood to a manageable
chronic disease (Bush and Gotz 2006).
Moreover, incorporating cystic fibrosis into the New
Zealand newborn screening programme was a landmark
event, one where screening is implemented despite the fact
that the condition does not strictly interface with the official
criteria. More recently, research from Australia and else-
where has shown good clinical benefit from screening, and
it is now being implemented throughout North America and
other countries and states (Green et al. 2006).
The cystic fibrosis case highlights aspects of decision mak-
ing that are not anticipated in the WHO or New Zealand
screening criteria. Evidence of improved outcomes to the
existing natural progression of the diseases was not certainly
known in advance of the screening that allowed those improve-
ments to occur. The experience of treating physicians was an
important consideration, along with the support of advocacy
groups keen to improve health outcomes for families.
Thus, it seems that in ground-level situations, a pragmatic
ethic adopted by healthcare systems can overrule the
pre-established framework stemming from the original
WHO or New Zealand screening criteria. But what does this
tell us about those criteria? In the next section, we utilize the
ground-level experience and decision making to critique
aspects of the WHO and New Zealand screening criteria.
Ethical frameworks for newborn screening decisions
The ‘Four Principles’ medical ethics framework (Beauchamp
and Childress 2001) is widely accepted at an international
level, and offers a broad consideration of issues within the
medical ethics field. This is not unexpected, for the framework
highlights principles that are highly relevant to the field of
medicine: respect for autonomy, beneficence, avoiding harm
and justice. Although, in theory, the WHO and New Zealand
screening criteria comply well with it, in practice, their appli-
cation matters a great deal. For example, if benefits and harms
are applied as though to an adult, one outcome may result;
another outcome may emerge from these principles as applied
to a newborn baby if the interests of this young child are seen
as intertwined and perhaps inseparable at that stage of life
from the close interests of parents and family. Benefits to a
family might be an indirect but still significant benefit to the
newborn (Bailey et al. 2005; Burchbinder and Timmermans
2011; Wilcken 2012). In order to tease out the complexity of
the ethical issues that arise in practice, and consider how they
might be appropriately applied, we now briefly focus on some
concrete examples from the New Zealand context. These
principles, derived from this context, directly contrast with
the criteria outlined in the Wilson and Jungner formula, and
we examine the processes by which they may be weighed up
and implemented, in contradiction to standard procedures.
Screening for conditions where the evidence is uncertain
or unavailable
Globally, it is estimated that there are 6,000 to 8,000 different
rare disorders that have prevalence of less than 1 per 2,000
people in the European population or fewer than 200,000
people in the USA (European Commission Position
Statement on Rare Diseases and Orphan Drugs 2010). The
subsequent lack of an evidence base for rare disorders is thus a
sticking point when it comes to the seventh criterion outlined
by Wilson and Jungner, which pivots around an emphasis on
screening for diseases that are ‘adequately understood’. It also
raises the issue of finding a balance between benefits and
harms. All of the conditions that are currently in the newborn
metabolic screening programme are rare, as are the candidates
for subsequent inclusion. A ‘comprehensive natural history’ of
rare disorders is often not available, and it may be unethical or
impossible to attempt controlled trials in such severe diseases
when treatment or other intervention has become available.
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Even the highly successful PKU programme had some
benign forms picked up when that programme started, giv-
ing rise to false positive results. This resulted in some
associated harms such as unnecessary parental anxieties
and the restriction of protein in the diet of a growing child,
and action was required to adapt the programme and man-
agement of those identified (Gurian et al. 2006; Hewlett and
Waisbren 2006). In such contexts, a strict and cautious
application of the criteria may not be the best approach.
Instead, weighing the expected benefits against possible
anticipated harms may guide physicians and administrators
towards screening, rather than not. Here, personal judg-
ments made about individual circumstances are arguably
as valid as strict criteria and formulas. This is perhaps
highlighted by recent research where 40 years on, individu-
als diagnosed and treated for PKU in New Zealand still see
themselves as part of a ‘living experiment’ with no known
ultimate outcomes (Frank et al. 2007)
The opportunity cost of the proposed screening
The ethical issue behind some criticisms of newborn screen-
ing pivots around the ‘Justice Principle’ (Bailey and Murray
2008; Rawls 1971, 2001), which emphasizes the distribu-
tion of risks and benefits across populations in an equitable
fashion. Here, the argument is that better health gains might
be obtained by investing financial resources in other parts of
the health system, and is implicated in the ninth criteria
outlined by Wilson and Jungner (1968). Namely, the costs
of diagnosis and treatment for specific conditions should be
financially weighed against potential medical expenditure,
as a whole. Whilst the wise use of resources is an important
political and ethical consideration, it can be applied in such
an overly simplistic way that important medical interven-
tions and programmes are excluded as funding priorities.
The counterbalancing argument within the Justice Principle is
that cases with serious impact and severe outcomes also need
special consideration. Treating like cases alike can be rephrased
as treating unequal cases unequally. That is, different criteria
might apply, or different weighting given within criteria, for
unusual situations that do not fit typical scenarios. This may lead
to prioritization for the most serious and urgent situations, rather
than to the widest spread of health gains across a population.
Submissions from the Access to Medicines Coalition (2007)
to the Ministry of Health on the development of a medicine
strategy for New Zealand provides a valuable discussion on this
issue. The submission from the Access to Medicines Coalition
to the Ministry of Health on the development of a medicine
strategy for New Zealand. The core of the counterargument is
that utilitarian analysis needs a certain level of sophistication,
and it must incorporate social context and community values to
be a useful tool for analysis and decision making.
Without the additional dimension of social and commu-
nity values, a rather crude utilitarian analysis that takes a
whole population approach might favour widely distributed
health gains for the maximum number of people. By con-
trast, a sophisticated utilitarian analysis might tend to favour
those most at risk of severe consequences, with urgency of
need influencing how priorities are set, thus providing spe-
cial consideration in special circumstances.
This approach is well established in emergency care. It is
also reflected in New Zealand health policy, with priority
given to the health needs of Maori and other population
groups. It can arguably be an appropriate consideration for
rare diseases that have fatal or severely disabling impacts.
However, we note that neither the WHO nor the New
Zealand screening criteria provide guidance on this point.
Screening for later onset and untreatable childhood
diseases
Late onset and untreatable conditions directly violate the
third and fourth criteria outlined by Wilson and Jungner
(1968), with neither readily identifiable symptoms nor ade-
quate treatment options. While proposals to screen for such
diseases might be readily rejected at first glance, there are
valid reasons for giving them serious consideration in the
newborn context. The potential negative aspects are the
affront to autonomy and apparent lack of benefits for the
baby in gaining knowledge that might appear to bring only
harm, and the denial of ordinary life experiences unencum-
bered by the certainty of impending disease impacts.
Many critics of expanded screening argue that neonatal
screening can only be justified if the child (the person to be
screened) can be expected to benefit directly, and such a
view would exclude expansion into conditions that appear
later in childhood and which may have limited treatment
options. In contrast, within patient/family advocacy groups,
there has been widespread discussion about the opportunity
to learn about an inherited disease in a child, prior to the
birth of a second or third child who might potentially be
affected (Wilcken 2012). Another perceived benefit is
avoiding the “diagnostic odyssey” associated with complex
diseases that present with subtle symptoms in the first
months or years. This odyssey can be particularly stressful
for families as uncertainty and possibly incorrect diagnosis
and inappropriate interventions are experienced.
When advances in screening technologies indicate that
particular diseases may be candidates for newborn testing,
the associated benefits for affected families provide a sig-
nificant argument for their consideration. Prime examples
are lysosomal storage diseases and Fragile X syndrome.
Both of these disease groups frequently present with subtle
or minimal symptoms for several years, and when a second
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or third child is born before the first is diagnosed, families
with two or more affected children are certainly not excep-
tions in our society.
Within advocacy groups, the arguments are well re-
hearsed, including the principle that ‘benefit to the family
is also a benefit to the child’. The policy statement of the
Human Genetics Society of Australasia (2011) and the
American College of Medical Geneticists (Burchbinder
and Timmermans 2011) also makes explicit reference to this
principle. However, these societies are in a minority of
professional groups that clearly articulate this point. As
these examples demonstrate the WHO criteria can be cri-
tiqued using a grounded approach, hence providing an ar-
gument for newborn screening of particular rare disorders.
As we have argued, this has already occurred in practice
within the New Zealand context. However, a notable feature
of some critics’ arguments is the potential for harm associ-
ated with the early identification of a disease, serving as a
reason not to add them to a screening programme. This has
led to a ‘do nothing’ approach where such potential harms
are perceived, without problematizing the consequences of
not acting (Pollitt 2006).
As Pollitt (2006) notes, despite the possible harm of
expanding too soon without detailed evidence and data,
there can also be substantial costs in harms from a ‘do
nothing’ approach. A challenge to that approach may come
from the ethical framework proposed by Bernheim et al.
(2007). This three-part framework proposes an analysis of
any ethical issues, followed by an evaluation of the ethical
dimensions of alternative actions, and after weighing the
two against one another, the provision of justification for
any action to be taken. This framework would offer a chance
for wider considerations of actions and consequences, leav-
ing aside a strict rule-based approach and allowing a wider
range of factors to be considered. Our observations suggest
that this is what has happened in practice when some inno-
vations in newborn screening have been decided upon.
Public policy: ethics, rights and duty
‘Respect for persons’ is more than simply a focus on auton-
omy, consent and protection of the individual’s interests. In
today’s world, it means direct stakeholder involvement in
system planning and decision making. As the New Zealand
case study has demonstrated, in the context of newborn
screening, it should also mean factoring in the family’s
interests into the criteria outlined in policy documents.
Examples of the application of such criteria to related areas
that we are familiar with include: genetic services staff
debating the genetic testing of siblings and an HGSA ethics
committee considering policies on the genetic testing of
minors.
Observation of the processes and reading literature on the
topic suggest that for some involved in screening policy and
practice, the criteria they work to can sometimes become an
end in themselves. In contrast to the criticism often leveled
at families, that they are too emotional or subjective in their
approach to such issues, some policy makers may be, iron-
ically, too “close” to the administrative and economic issues
at hand and the “formula” that often evolves from the
criteria to be sufficiently objective. Furthermore, they may
also be too far removed from the immediacy of the family
and patient experience to be sufficiently subjective, and thus
empathetic, in their decision making. With no experience of
living on a day-to-day basis with the disorders under con-
sideration, or even unfamiliarity with them, policy officials
may lack insight into the implications of their actions for the
affected families.
A better blend of decision-making interests that closely
involves patient/family interests is required. In New
Zealand, such a principle is well supported by provisions
in the Public Health and Disability Act 2000, including S3
(c) providing for a community voice, and S22 (1), (g), (h)
and (i) with their emphasis on social responsibility, commu-
nity engagement and ethical standards. But the question
remains as to how these ethical implications should be
factored into decision making.
In response to this question, we propose a pragmatic ethic
for consideration, with action in the face of uncertainty or in
the face of questionable cost-effectiveness. That is, when
knowledge of biological causes and the technical capacity to
intervene intersect, professionals and administrators within
the health system are faced with an emerging duty to act,
and the implicated families/patients have an emerging right
to services within the health system. While these duties and
rights may not always be absolute, or legally enforceable
due to the constraints of competing health demands and
limited resources, there is, arguably, still an ethical respon-
sibility for the health system to respond in a timely, consid-
ered manner to patient and family needs.
We propose that both the right and the duty are elevated
by the seriousness and urgency associated with particular
disease groups. Thus, in the context of screening, priority
should be given to appropriate assessments of the potential
and suitability of a disease, as opposed to the ongoing
delays that seem to characterize many potential screening
situations. The three-part framework of Bernheim et al.
(2007) would seem very apt for this situation.
In the New Zealand context, one such example of an
intervention of rights and duty in a policy decision was the
Health & Disability Commissioner’s ruling on antenatal
HIV screening that occurred in June 2005. The National
Health committee considered the case for an antenatal
screening programme for HIV and recommended against
such a step, but a complaint to the Health and Disability
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Commissioner resulted in his review of the rights of patients
under the Health and Disability Consumers Code of Rights,
and concluding:
“Given the state of knowledge about HIV infection
and the availability of treatment to prevent perinatal
transmission, in my view, women receiving antenatal
care in New Zealand in 1999 were entitled to a com-
prehensive pregnancy risk assessment that included
assessment of the risk of HIV infection” (Health and
Disability Commissioner 2005).
The comments from the Commissioner relate to a partic-
ular set of circumstances, but they may well be as applicable
to newborn metabolic screening as they are to antenatal
screening. Indeed, they could hold particular significance
for many potential screening initiatives around the antenatal
and newborn period, as well as those recently implemented,
including newborn hearing, antenatal fetal aneuploidy, an-
tenatal HIV and expanded newborn metabolic screening.
Most of those were very slow to reach implementation,
and it appears that whilst there was a significant level of
data and evidence to support their application, in practice,
bureaucratic malaise was the major impediment to the start
of these programmes.
Conclusion—a paradigm shift
This article identifies what appears to be a paradigm shift in
the implementation of newborn screening. Other authors
have noted this, but with varying degrees of acceptance that
issues such as the interests of the patient’s family should be
part of the decision criteria (Seymour et al. 1997). This
participation is supported by the principle of acceptability
to those screened, or to those consenting on their behalf, as
well as consistency with many other trends in decision
making in society.
In the New Zealand context, decisions to implement
antenatal HIV screening programmes and cabinet decisions
on antenatal Down syndrome screening also demonstrate
that formulaic application of screening criteria is not enough
(New Zealand Ministry of Health, 2007). Both decisions
included other factors and effectively broadened the stan-
dard criteria to incorporate wider ethical, legal and social
considerations. Such matters are increasingly being ac-
knowledged in the final decision on whether to screen or
not. In other jurisdictions, such as some US States’ deci-
sions on a variety of new screening initiatives, wishes of
families appear to have significant influence.
While all screening criteria could usefully be reviewed in
the light of animated debates about screening practices,
newborn metabolic screening criteria in particular need
close scrutiny and change in the light of the important
social, political and ethical aspects that should be in-
cluded. In light of our analysis of screening in New
Zealand, and from observation of screening literature
and practices in other jurisdictions, we propose that
for screening in the newborn period, the following ad-
ditional criteria should apply:
& Screening in the absence of an accepted treatment may
be appropriate when it will provide information of ben-
efit to the child or the family.
& Benefit or harm to the family should be considered a
benefit or harm to the child.
& Decisions about screening should include community
values, rights and duties alongside any cost-effectiveness
assessment.
& Action in the face of uncertainty may be justified in
exceptional circumstances.
Widening criteria for screening the newborn period, as
proposed, will allow a far more accommodating balance of
interests, and adapt historic generic screening criteria to
reflect contemporary circumstances, knowledge and values,
including particularities of the newborn situation.
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